Arcus Biosciences Announces That Domvanalimab Plus Zimberelimab Improved Overall Survival In ARC-10, A Randomized Study In Patients With PD-L1-High Non-Small Cell Lung Cancer; A 36% Reduction In Risk Of Death Was Observed
Arcus Biosciences Announces That Domvanalimab Plus Zimberelimab Improved Overall Survival In ARC-10, A Randomized Study In Patients With PD-L1-High Non-Small Cell Lung Cancer; A 36% Reduction In Risk Of Death Was Observed
- Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy
- A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached
- Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%)
- Arcus will discuss these results on its earnings call at 2:00 PM PT / 5:00 PM ET Wednesday, November 6, 2024
- Domvanalimab加zimberelimab與單獨使用zimberelimab或化療相比，與較高的無進展生存期、總生存期和客觀緩解率相關聯
- 與單獨使用zimberelimab相比，domvanalimab加zimberelimab的死亡風險減少36%（風險比=0.64）；zimberelimab的中位總生存期爲兩年，而domvanalimab加zimberelimab的中位總生存期尚未達到
- 相對於化療，domvanalimab和zimberelimab組合導致的治療相關不良事件導致的治療中斷率較低（10.5% vs 23.5%）
- Arcus將在2024年11月6日星期三美國太平洋時間下午2:00 / 東部時間下午5:00的業績會上討論這些結果
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with front-line locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. This study was conducted in partnership with Gilead Sciences. These results will be presented on November 8 in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting by Melissa L. Johnson, M.D., Director of the Lung Cancer Research Program, Sarah Cannon Research Institute, and investigator for the ARC-10 study.
Arcus Biosciences, Inc.（紐交所:RCUS）是一家處於臨床階段的全球生物製藥公司，專注於爲癌症患者開發不同的分子和聯合療法。今日宣佈了ARC-10第1部分的結果，這是一項隨機、開放標籤的三臂研究，評估了Fc-靜默抗TIGIt單克隆抗體domvanalimab，與抗PD-1單克隆抗體zimberelimab（DZ）相結合，與zimberelimab（Z）或化療在具有PD-L1腫瘤比例評分（TPS）≥50%的一線局部晚期或轉移性鱗狀或非鱗狀非小細胞肺癌（NSCLC）患者進行，且不存在任何已批准靶向治療的腫瘤基因異常或驅動突變。該研究與吉利德科學合作進行。這些結果將由Melissa L. Johnson博士，肺癌研究項目主任，Sarah Cannon研究院，ARC-10研究的調查員，在2024年11月8日的癌症免疫治療學會（SITC）2024年年會的晚期展板報告會上提交。
譯文內容由第三人軟體翻譯。
